
Early intervention in Multiple Sclerosis: the role of high-efficacy therapies in long-term outcomes (certified by Paradigms)
About this e-learning
Welcome! This e-learning course explores the role of early high-efficacy treatment strategies in Multiple Sclerosis (MS), with a focus on their potential impact on long-term clinical outcomes. Drawing on evidence from clinical trials, international registries, and emerging biomarker research, the course examines how treatment timing and therapeutic strategies may influence disease progression and long-term neurological health.
Through expert presentations by Tjalf Ziemssen and Bart Van Wijmeersch, the course reviews evidence comparing early high-efficacy treatment with escalation strategies, focusing on disability progression, disease activity, and long-term brain health.
This course provides neurologists and related healthcare professionals with evidence-based insights to support individualized treatment decisions. It highlights the importance of integrating clinical evidence, prognostic biomarkers, and patient-specific risk–benefit considerations when selecting therapeutic strategies aimed at preserving long-term brain health.
Certificate
Please note that this e-learning is certified by the Paradigms Foundation.
Participants who complete the e-learning will receive a Paradigms Foundation certificate upon completion.
Once you confirmed you participated, you will be able to download your Certificate of Participation from ‘Your Account‘.
How to confirm your participation: complete this e-learning course (it includes one section, one satisfaction survey and one exam).
Learning objectives
By completing this course, participants will be able to:
- Apply evidence-based insights to individualized treatment decisions.
- Understand the benefits and challenges of early high-efficacy treatment in MS.
- Compare early intensive treatment with traditional escalation strategies.
- Examine the impact of treatment timing on long-term disability progression.
- Explore the role of biomarkers and progression independent of relapse activity (PIRA).
